<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">06498</article-id><article-id pub-id-type="doi">10.7554/eLife.06498</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-24283"><name><surname>Jeay</surname><given-names>Sébastien</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-27394"><name><surname>Gaulis</surname><given-names>Swann</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-27395"><name><surname>Ferretti</surname><given-names>Stéphane</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-27396"><name><surname>Bitter</surname><given-names>Hans</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-27397"><name><surname>Ito</surname><given-names>Moriko</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-27398"><name><surname>Valat</surname><given-names>Thérèse</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-27399"><name><surname>Murakami</surname><given-names>Masato</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-27400"><name><surname>Ruetz</surname><given-names>Stephan</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-27401"><name><surname>Guthy</surname><given-names>Daniel A</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-27402"><name><surname>Rynn</surname><given-names>Caroline</given-names></name><aff><institution content-type="dept">Metabolism and Pharmacokinetics</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-27403"><name><surname>Jensen</surname><given-names>Michael R</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf12"/></contrib><contrib contrib-type="author" id="author-27404"><name><surname>Wiesmann</surname><given-names>Marion</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf13"/></contrib><contrib contrib-type="author" id="author-27405"><name><surname>Kallen</surname><given-names>Joerg</given-names></name><aff><institution content-type="dept">Center of Proteomic Chemistry</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf14"/></contrib><contrib contrib-type="author" id="author-27406"><name><surname>Furet</surname><given-names>Pascal</given-names></name><aff><institution content-type="dept">Global Discovery Chemistry</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf15"/></contrib><contrib contrib-type="author" id="author-27407"><name><surname>Gessier</surname><given-names>François</given-names></name><aff><institution content-type="dept">Global Discovery Chemistry</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf16"/></contrib><contrib contrib-type="author" id="author-27408"><name><surname>Holzer</surname><given-names>Philipp</given-names></name><aff><institution content-type="dept">Global Discovery Chemistry</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf17"/></contrib><contrib contrib-type="author" id="author-27409"><name><surname>Masuya</surname><given-names>Keiichi</given-names></name><aff><institution>Peptidream Inc</institution>, <addr-line><named-content content-type="city">Tokyo</named-content></addr-line>, <country>Japan</country></aff><xref ref-type="fn" rid="conf18"/></contrib><contrib contrib-type="author" id="author-27411"><name><surname>Würthner</surname><given-names>Jens</given-names></name><aff><institution content-type="dept">Translational Clinical Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf19"/></contrib><contrib contrib-type="author" id="author-27410"><name><surname>Halilovic</surname><given-names>Ensar</given-names></name><aff><institution content-type="dept">Translational Clinical Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf20"/></contrib><contrib contrib-type="author" id="author-27412"><name><surname>Hofmann</surname><given-names>Francesco</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf21"/></contrib><contrib contrib-type="author" id="author-15959"><name><surname>Sellers</surname><given-names>William R</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf22"/></contrib><contrib contrib-type="author" corresp="yes" id="author-24280"><name><surname>Graus Porta</surname><given-names>Diana</given-names></name><aff><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country><email>diana.graus_porta@novartis.com</email></aff><xref ref-type="fn" rid="conf23"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1082"><name><surname>Espinosa</surname><given-names>Joaquin M</given-names></name><role>Reviewing editor</role><aff><institution>University of Colorado Boulder</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>12</day><month>05</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e06498</elocation-id><supplementary-material><ext-link xlink:href="elife-06498-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>15</day><month>01</month><year>2015</year></date><date date-type="accepted"><day>11</day><month>05</month><year>2015</year></date></history><permissions><copyright-statement>© 2015, Jeay et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Jeay et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53-HDM2 inhibitor NVP-CGM097, currently under evaluation in clinical trials. By intersecting high-throughput cell line sensitivity data with genomic data, we have identified a gene expression signature consisting of 13 up-regulated genes that predicts for sensitivity to NVP-CGM097 in both cell lines and in patient-derived xenograft models. Interestingly, these 13 genes are known p53 downstream target genes, suggesting that the identified gene signature reflects the presence of at least a partially activated p53 pathway in NVP-CGM097 sensitive tumors. Together, our findings provide evidence for the use of this newly identified predictive gene signature to refine the selection of patients with wild-type p53 tumors and increase the likelihood of response to treatment with p53-HDM2 inhibitors, such as NVP-CGM097.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Sébastien Jeay, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf3"><p>Swann Gaulis, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf4"><p>Stéphane Ferretti, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf5"><p>Hans Bitter, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf6"><p>Moriko Ito, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf7"><p>Thérèse Valat, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf8"><p>Masato Murakami, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf9"><p>Stephan Ruetz, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf10"><p>Daniel A Guthy, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf11"><p>Caroline Rynn, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf12"><p>Michael R Jensen, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf13"><p>Marion Wiesmann, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf14"><p>Joerg Kallen, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf15"><p>Pascal Furet, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf16"><p>François Gessier, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf17"><p>Philipp Holzer, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf18"><p>Keiichi Masuya, was an employee of Novartis Institutes for BioMedical Research and is now an employee of Peptidream Inc. and has ownership interest (including patents) in Peptidream Inc.</p></fn><fn fn-type="conflict" id="conf19"><p>Jens Würthner, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf20"><p>Ensar Halilovic, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf21"><p>Francesco Hofmann, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf22"><p>William R Sellers, Employee of Novartis Institutes for BioMedical Research. Holds the position of VP/Global Head of Oncology in Novartis Institutes for BioMedical Research and has ownership interest (including patents) in Novartis Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf23"><p>Diana Graus Porta, Employee of Novartis Institutes for BioMedical Research.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal studies were conducted in accordance to procedures covered by permit number 1975 issued by the Kantonales Veterinäramt Basel-Stadt and strictly adhered to the Eidgenössisches Tierschutzgesetz and the Eidgenössische Tierschutzverordnung. All animals were allowed to adapt for 4 days and housed in a pathogen-controlled environment (5 mice/Type III cage) with access to food and water ad libitum and were identified with transponders.</p></fn></fn-group></back></article>